drugset / Trial / NCT03199261

A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects

NCT03199261

Phase 1 Completed 24 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

Evaluation of the pharmacokinetics and safety rE-4 Injection versus rE-4 Freeze-dried Powder in healthy subjects.

Timeline

Start
2016-12-23
Primary completion
2017-01-21
Completion
2017-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug